• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于下一代腺病毒载体的严重急性呼吸综合征冠状病毒2疫苗

Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2.

作者信息

Murala Muralimanohara S T, Gairola Vivek, Sayedahmed Ekramy E, Mittal Suresh K

机构信息

Department of Comparative Pathobiology, Purdue Institute of Inflammation, Immunology and Infectious Disease, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907-2027, USA.

出版信息

Vaccines (Basel). 2025 Apr 14;13(4):406. doi: 10.3390/vaccines13040406.

DOI:10.3390/vaccines13040406
PMID:40333307
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12031563/
Abstract

This review systematically revises adenovirus (Ad) biology, vector structure, immune responses, and currently available Ad vector COVID-19 vaccines. It analyzes the challenges associated with the Ad vector-based vaccines, including preexisting vector immunity and other side effects. Moreover, this review explores novel and innovative strategies to overcome these constraints for developing next-generation vaccines for broad protection to cover emerging SARS-CoV-2 variants. The future refinement of Ad vaccine platforms will be pivotal in achieving durable immunity against emerging variants for global preparedness.

摘要

本综述系统地修订了腺病毒（Ad）生物学、载体结构、免疫反应以及目前可用的腺病毒载体COVID-19疫苗。它分析了与腺病毒载体疫苗相关的挑战，包括预先存在的载体免疫和其他副作用。此外，本综述探讨了新颖和创新的策略，以克服这些限制，开发下一代疫苗，实现广泛保护，以应对新出现的SARS-CoV-2变体。腺病毒疫苗平台的未来改进对于实现针对新出现变体的持久免疫力以实现全球防备至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc7/12031563/f6381e2e4686/vaccines-13-00406-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc7/12031563/48ee1292f652/vaccines-13-00406-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc7/12031563/b039b231d60e/vaccines-13-00406-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc7/12031563/17d8292794dc/vaccines-13-00406-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc7/12031563/f6381e2e4686/vaccines-13-00406-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc7/12031563/48ee1292f652/vaccines-13-00406-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc7/12031563/b039b231d60e/vaccines-13-00406-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc7/12031563/17d8292794dc/vaccines-13-00406-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc7/12031563/f6381e2e4686/vaccines-13-00406-g004.jpg

相似文献

1
Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2.基于下一代腺病毒载体的严重急性呼吸综合征冠状病毒2疫苗
Vaccines (Basel). 2025 Apr 14;13(4):406. doi: 10.3390/vaccines13040406.
2
A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines.COVID-19 腺病毒载体疫苗接种者的疫苗诱导性血栓性血小板减少症的系统评价。
J Thromb Thrombolysis. 2022 May;53(4):798-823. doi: 10.1007/s11239-021-02626-w. Epub 2022 Feb 14.
3
Bovine Adenoviral Vector-Based Platform for Vaccine Development.基于牛腺病毒载体的疫苗开发平台。
Vaccines (Basel). 2025 May 3;13(5):494. doi: 10.3390/vaccines13050494.
4
Vaccine-Induced Immune Thrombotic Thrombocytopenia Caused by Zoetis PR-VAC PLUS in Pseudorabies Virus-Free Danish Purebred Pigs.硕腾PR-VAC PLUS疫苗在无伪狂犬病病毒的丹麦纯种猪中引起的疫苗诱导免疫性血栓性血小板减少症
Vet Med Sci. 2025 Mar;11(2):e70222. doi: 10.1002/vms3.70222.
5
Developing the next-generation of adenoviral vector vaccines.开发下一代腺病毒载体疫苗。
Hum Vaccin Immunother. 2025 Dec;21(1):2514356. doi: 10.1080/21645515.2025.2514356. Epub 2025 Jul 1.
6
Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review.疫苗接种后 COVID-19 疫苗诱导的免疫性血栓性血小板减少症和脑静脉窦血栓形成：系统评价。
J Neurol Sci. 2021 Sep 15;428:117607. doi: 10.1016/j.jns.2021.117607. Epub 2021 Aug 3.
7
Efficacy and safety of COVID-19 vaccines.新型冠状病毒疫苗的有效性和安全性。
Cochrane Database Syst Rev. 2022 Dec 7;12(12):CD015477. doi: 10.1002/14651858.CD015477.
8
VITT Pathophysiology: An Update.疫苗诱导的血栓性血小板减少症（VITT）的病理生理学：最新进展
Vaccines (Basel). 2025 Jun 17;13(6):650. doi: 10.3390/vaccines13060650.
9
Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum Protection.不断演变的新冠病毒疫苗：从当前解决方案到广谱保护
Vaccines (Basel). 2025 Jun 12;13(6):635. doi: 10.3390/vaccines13060635.
10
Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.恒河猴腺病毒载体的免疫原性和交叉反应性。
J Virol. 2018 May 14;92(11). doi: 10.1128/JVI.00159-18. Print 2018 Jun 1.

引用本文的文献

1
Single-Dose Intranasal or Intramuscular Administration of Simian Adenovirus-Based H1N1 Vaccine Induces a Robust Humoral Response and Complete Protection in Mice.基于猿猴腺病毒的H1N1疫苗单剂量鼻内或肌肉注射给药可在小鼠中诱导强烈的体液反应并提供完全保护。
Viruses. 2025 Aug 5;17(8):1085. doi: 10.3390/v17081085.

本文引用的文献

1
A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection.一种二价新冠病毒mRNA疫苗引发了广泛的免疫反应并提供了针对奥密克戎亚变体感染的保护。
NPJ Vaccines. 2025 Jan 10;10(1):4. doi: 10.1038/s41541-025-01062-8.
2
Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variants.二价奥密克戎BA.1疫苗加强针可增加记忆B细胞广度以及针对新出现的新冠病毒变种的中和抗体。
EBioMedicine. 2024 Dec;110:105461. doi: 10.1016/j.ebiom.2024.105461. Epub 2024 Nov 28.
3
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
ChAdOx1 nCoV-19（AZD1222）疫苗在肯尼亚成年人中的安全性和免疫原性：一项1/2期单盲随机对照试验。
Wellcome Open Res. 2023 Nov 27;8:182. doi: 10.12688/wellcomeopenres.19150.2. eCollection 2023.
4
Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.Ad26.COV2.S 成人安全性和免疫原性：一项随机、双盲、安慰剂对照的 2a 期剂量探索研究。
Vaccine. 2024 Jun 11;42(16):3536-3546. doi: 10.1016/j.vaccine.2024.04.059. Epub 2024 May 4.
5
Vaccination with Adenovirus Type 5 Vector-Based COVID-19 Vaccine as the Primary Series in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Clinical Trial.5型腺病毒载体新冠疫苗作为成人主要接种程序的疫苗接种：一项随机、双盲、安慰剂对照的1/2期临床试验
Vaccines (Basel). 2024 Mar 11;12(3):292. doi: 10.3390/vaccines12030292.
6
The Production of Complement Inhibitor Proteins in Mammalian Cell Lines-Light at the End of the Tunnel?哺乳动物细胞系中补体抑制蛋白的生产——曙光在前？
Biomedicines. 2024 Mar 14;12(3):646. doi: 10.3390/biomedicines12030646.
7
Strategy to develop broadly effective multivalent COVID-19 vaccines against emerging variants based on Ad5/35 platform.基于 Ad5/35 平台开发针对新兴变异株的广谱有效多价 COVID-19 疫苗的策略。
Proc Natl Acad Sci U S A. 2024 Mar 5;121(10):e2313681121. doi: 10.1073/pnas.2313681121. Epub 2024 Feb 26.
8
Development of NP-Based Universal Vaccine for Influenza A Viruses.基于纳米颗粒的甲型流感病毒通用疫苗的研发。
Vaccines (Basel). 2024 Feb 2;12(2):157. doi: 10.3390/vaccines12020157.
9
Mucosal vaccine-induced cross-reactive CD8 T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection.黏膜疫苗诱导的交叉反应性 CD8 T 细胞可预防 SARS-CoV-2 XBB.1.5 呼吸道感染。
Nat Immunol. 2024 Mar;25(3):537-551. doi: 10.1038/s41590-024-01743-x. Epub 2024 Feb 9.
10
Three immunizations with Novavax's protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2.接种三剂诺瓦瓦克斯公司的蛋白疫苗可增加抗体广度，并为抵御新冠病毒提供持久保护。
NPJ Vaccines. 2024 Jan 20;9(1):17. doi: 10.1038/s41541-024-00806-2.